Holen Sie sich die Stockscreener-App
8.03
2.43%
-0.20
Handel nachbörslich:
8.33
0.30
+3.74%
Schlusskurs vom Vortag:
$8.23
Offen:
$8.28
24-Stunden-Volumen:
1.14M
Relative Volume:
0.29
Marktkapitalisierung:
$629.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-209.96M
KGV:
-2.5411
EPS:
-3.16
Netto-Cashflow:
$-176.27M
1W Leistung:
-9.78%
1M Leistung:
-22.04%
6M Leistung:
-22.71%
1J Leistung:
-30.36%
1-Tages-Spanne:
$7.96
$8.545
1-Wochen-Bereich:
$7.96
$9.405
52-Wochen-Spanne:
$2.68
$14.80
Replimune Group Inc Stock (REPL) Company Profile
Firmenname
Replimune Group Inc
Sektor
Branche
Telefon
(781) 222-9600
Adresse
500 UNICORN PARK, WOBURN, MA
Vergleichen Sie REPL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
8.03 | 645.59M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-10-20 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | Hochstufung | Wedbush | Neutral → Outperform |
| 2025-09-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | Herabstufung | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-23 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-06-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2023-04-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-17 | Eingeleitet | BTIG Research | Buy |
| 2020-11-02 | Eingeleitet | Jefferies | Buy |
| 2020-10-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-09-04 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-25 | Eingeleitet | Wedbush | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Eingeleitet | JP Morgan | Overweight |
| 2018-08-14 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
Why Replimune Group Inc. stock remains a top recommendationNew Releases Roundup & HOKA model picks for your routine - ulpravda.ru
Why Replimune Group Inc. stock is seen as undervaluedCPI Data & Consistent Return Investment Signals - ulpravda.ru
How institutional buying supports Replimune Group Inc. stock - ulpravda.ru
Will Replimune Group Inc. stock reach all time highs in 20252026 world cup usa national team qualification star players possession football winner prediction expert opinion - ulpravda.ru
Replimune Group Sees Unusually High Options Volume (NASDAQ:REPL) - MarketBeat
Is Replimune Group (NASDAQ:REPL) A Risky Investment? - 富途牛牛
HC Wainwright & Co. Upgrades Replimune Group (REPL) - MSN
Replimune Group (NASDAQ:REPL) Shares Down 6.4%What's Next? - MarketBeat
Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months - MSN
Replimune announces priority review for its melanoma treatment - MSN
Replimune Group (NASDAQ:REPL) Trading Up 4.8%Should You Buy? - MarketBeat
Replimune Group Inc (HAM:7R8) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Is Replimune Group Inc. stock overvalued by current metricsWeekly Trend Recap & Consistent Income Trade Ideas - Улправда
How Replimune Group Inc. stock trades during market volatility2025 Volume Leaders & Daily Technical Stock Forecast Reports - Улправда
Why Replimune Group Inc. stock could benefit from AI revolution2025 Fundamental Recap & Weekly Return Optimization Alerts - Улправда
Is Replimune Group Inc. stock supported by strong fundamentalsJuly 2025 Setups & Smart Swing Trading Alerts - Улправда
Why hedge funds are buying Replimune Group Inc. stock2025 Dividend Review & Free Reliable Trade Execution Plans - DonanımHaber
Aug Catalysts: Why Replimune Group Inc. stock remains a top recommendation - Улправда
What sentiment indicators say about Replimune Group Inc. stockJuly 2025 Outlook & High Return Stock Watch Alerts - Улправда
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - TMX Newsfile
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Biotech pioneering oncolytic immunotherapies to speak at J.P. Morgan - Stock Titan
Replimune Shares Face Mounting Headwinds - AD HOC NEWS
Insiders At Replimune Group Sold US$766k In Stock, Alluding To Potential Weakness - simplywall.st
Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Replimune Group earns relative strength rating upgrade; hits key benchmark - MSN
What analysts say about Replimune Group Inc stockVolume Spike Alerts & Free Trading Signals to Sharpen Your Edge - earlytimes.in
Replimune Group, Inc. $REPL Holdings Trimmed by Braidwell LP - MarketBeat
Replimune Group (NASDAQ:REPL) Director Kapil Dhingra Sells 3,169 Shares - MarketBeat
Replimune Group, Inc. $REPL Shares Sold by Redmile Group LLC - MarketBeat
Replimune Group Director Kapil Dhingra Sells All Shares - TradingView — Track All Markets
[Form 4] Replimune Group, Inc. Insider Trading Activity - Stock Titan
Replimune Group, Inc. $REPL Shares Sold by Marshall Wace LLP - MarketBeat
Nan Fung Group Holdings Ltd Lowers Stock Position in Replimune Group, Inc. $REPL - MarketBeat
Replimune Group (REPL) Price Target Increased by 10.52% to 12.82 - Nasdaq
Insider Selling: Replimune Group (NASDAQ:REPL) CEO Sells 10,000 Shares of Stock - MarketBeat
Replimune Stock Presents a Complex Investment Narrative - AD HOC NEWS
Saturn V Capital Management LP Takes $1.20 Million Position in Replimune Group, Inc. $REPL - MarketBeat
Replimune Group CEO Sushil Patel Sells 10,000 Shares - TradingView
CEO Patel Sells 10,000 ($111.3K) Of Replimune Group Inc [REPL] - TradingView
Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) Investors - The National Law Review
Levi & Korsinsky Helps Retail Investors SueWallSt Over Alleged Fraud by Replimune Group, Inc. - The National Law Review
Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma DrugHagens Berman (PR Newswire) - Aktiellt
What Is Driving Replimune Stock’s 98% Surge Today? - MSN
Replimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Can One97 Communications Limited Deliver Consistent Free Cash FlowsVolume Spike Alerts & Swing Trade Smarter With Data Insights - earlytimes.in
Replimune Group Inc. stock volume spike explainedWeekly Stock Analysis & Short-Term Trading Alerts - newser.com
How Replimune Group Inc. stock reacts to global recession fearsMarket Trend Review & Smart Investment Allocation Insights - newser.com
Replimune Group (NASDAQ:REPL) Insider Sells $47,392.80 in Stock - MarketBeat
Will Replimune Group Inc. stock deliver shareholder valueQuarterly Trade Summary & Weekly Watchlist for Consistent Profits - newser.com
Using AI based signals to follow Replimune Group Inc.Bond Market & Long Hold Capital Preservation Tips - newser.com
Finanzdaten der Replimune Group Inc-Aktie (REPL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Replimune Group Inc-Aktie (REPL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dhingra Kapil | Director |
Dec 09 '25 |
Sale |
10.40 |
3,169 |
32,958 |
0 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):